GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Osiris Therapeutics Inc (NAS:OSIR) » Definitions » Price-to-Owner-Earnings

Osiris Therapeutics (Osiris Therapeutics) Price-to-Owner-Earnings : (As of May. 12, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Osiris Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-12), Osiris Therapeutics's share price is $18.99. Osiris Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Osiris Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


OSIR's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 35.03
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-12), Osiris Therapeutics's share price is $18.99. Osiris Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2018 was $1.06. Therefore, Osiris Therapeutics's PE Ratio (TTM) for today is 17.92.

As of today (2024-05-12), Osiris Therapeutics's share price is $18.99. Osiris Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $1.05. Therefore, Osiris Therapeutics's PE Ratio without NRI for today is 18.09.


Osiris Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Osiris Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Osiris Therapeutics Price-to-Owner-Earnings Chart

Osiris Therapeutics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 176.47 15.79

Osiris Therapeutics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 176.47 52.07 32.60 57.81 15.79

Competitive Comparison of Osiris Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Osiris Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Osiris Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Osiris Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Osiris Therapeutics's Price-to-Owner-Earnings falls into.



Osiris Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Osiris Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=18.99/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Osiris Therapeutics  (NAS:OSIR) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Osiris Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Osiris Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Osiris Therapeutics (Osiris Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
7015 Albert Einstein Drive, Columbia, MD, USA, 21046-1707
Osiris Therapeutics is a biotechnology company involved in researching, developing, and marketing cellular regenerative medicine products. The company's therapeutic areas focus on innovation in regenerative medicine, including bioengineering, stem cell research, and viable tissue-based products. Osiris has accomplished commercial success with products in orthopedics, sports medicine, and wound care, such as Cartiform, Ovation, and Grafix.
Executives
Reinhart Charles A. Iii director C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Linda L Chang officer: Chief Financial Officer ONE PARK PLACE, STE 450, ANNAPOLIS MD 21401
Shauna L Vernal officer: Chiel Legal Officer
Linda Palczuk officer: President & CEO 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
David L White director
Thomas J Knapp director 4640 SW MACADAM AVE., SUITE 270, PORTLAND OR 97239
Jonathan Mark Hopper officer: Chief Medical Officer 64 SIDNEY STREET, CAMBRIDGE MA 02139
Jacoby Philip R Jr officer: Principal Accounting Officer
C Randal Mills director, officer: President & CEO 18366 CALLE STELLINA, RANCHO SANTA FE CA 92091
Jay M Moyes director
Stephen W Potter officer: Senior Vice President 7015 ALBERT EINSTEIN DR, COLUMBIA MD 21046
Gregory Hurd Barnhill director

Osiris Therapeutics (Osiris Therapeutics) Headlines

From GuruFocus